Yihui Biotechnology

Yihui (Shanghai) Biotechnology is a clinical-stage biopharmaceutical company focused on the development of innovative multi-specific antibodies for cancer immunotherapy. Headquartered in Shanghai, the company specializes in T-cell engagers (TCEs) designed to recruit and activate the patient's own immune system to target tumor cells. Its lead candidate, YH001, is a bispecific antibody targeting CD38 and CD3, currently undergoing Phase 1 clinical trials for the treatment of relapsed or refractory multiple myeloma. The company's pipeline also includes pre-clinical programs targeting BCMA and GPRC5D, as well as other undisclosed tumor antigens. Yihui Biotechnology is led by a management team with deep expertise in antibody engineering from leading global pharmaceutical firms and is backed by prominent venture capital investors.